Everest Medicines will announce its full-year 2025 financial results on March 26, 2026

Shanghai - March 10, 2026 - Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative medicines, announced today that it will release its full-year 2025 financial results and business updates on March 26, 2026, Beijing time. An earnings conference call in both English and Chinese will be held online on the same day.

The English session will be held at 8:00 AM Beijing time on March 26, 2026 (8:00 PM Eastern Time on March 25); the Chinese session will take place at 9:30 AM Beijing time on the same day (9:30 PM Eastern Time on March 25).

Participants can join the English and Chinese meetings via the following links:

English Meeting:

Meeting time:Thursday, March 26, 2026, at 8:00 AM Beijing time (8:00 PM Eastern Time on March 25)

Advance registration link: https://www.acecamptech.com/eventDetail/60532508

Live webcast link: https://www.acecamptech.com/meeting_live/70534610/855957?event_id=60532508

Meanwhile, participants can also dial into the teleconference using the following information:

United States: +1 646 2543594 (EN);

Mainland China: +86 10 58084166 (EN);

+86 10 58084199 (CN);

Hong Kong, China: +852 30051313 (EN);

+852 30051355 (CN);

United Kingdom: +44 12 13680466 (EN);

Global: +1 646 2543594 (EN);

Conference password: 973808

Chinese conference:

Meeting time:Beijing time, March 26, 2026, Thursday, 9:30 AM (US Eastern Time, March 25, 9:30 PM)

Live conference link: https://s.comein.cn/1g342i3i

Meanwhile, participants can also dial into the teleconference using the following information:

Mainland China: +86-4001888938

Global: +86-01053827720

Taiwan, China: +886-277083288

Hong Kong, China: +852-51089680

Access code: 531077

After the English conference concludes, you can listen to the English conference replay by visiting the Everest Medicines official website (http://www.everestmedicines.com).

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, committed to addressing unmet medical needs in global markets. The management team of Everest Medicines possesses deep expertise and extensive experience from leading pharmaceutical enterprises in China and globally. The company owns a commercial-scale global production base in Jiashan, Zhejiang, constructed strictly in accordance with the GMP requirements of the National Medical Products Administration (NMPA) and the European Medicines Agency (EMA), as well as the WHO PQ standards.

The company focuses on CKM (cardiovascular, renal, and metabolic), autoimmune diseases, ophthalmology, and critical care treatment areas. It has built a commercialization platform that integrates an omnichannel commercial system with full lifecycle commercial capabilities for pharmaceuticals. Leveraging its proprietary mRNA platform, which holds global rights, the company is advancing existing pipelines such as mRNA in vivo CAR-T and mRNA cancer vaccines. Meanwhile, through the introduction and incubation of potential platforms, it expands R&D capabilities while strengthening its global presence and accelerating international development. For more information, visit the company's official website: www.everestmedicines.com.

Forward-Looking Statements:

This press release may contain certain forward-looking statements based on the company’s or management’s current views, beliefs, and expectations regarding the company’s business operations and financial condition at the time of making the statements. These statements may include terms such as “will,” “expect,” “forecast,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “confident,” and other similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company’s control and difficult to predict. Therefore, actual results may differ materially from those implied in the forward-looking statements due to various factors and assumptions, including changes and developments in our business, competitive environment, political, economic, legal, and social conditions. Neither the company nor its subsidiaries, directors, officers, advisors, or agents assume any obligation to update the forward-looking statements contained in this release to reflect subsequent information, future events, or circumstances unless required by law.

35K Views